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Abstract
Chronic constipation (CC) is an extremely common condition with an estimated prevalence of up to 24%. Most patients with
CC should be treated in primary care. Changes in lifestyle, including increased intake of dietary fibre, fluid, and exercise,
should be attempted in most patients. Osmotic or stimulant laxatives are indicated if there are insufficient effects of lifestyle
changes. Prokinetics and secretagogues should be restricted to those not responding to basic treatment. Anorectal physi-
ology tests and assessment of colorectal transit time are indicated if medical treatment fails or if symptoms indicate severely
obstructed defecation. If symptoms indicate an underlying structural disorder, barium or magnetic resonance evacuation
proctography is indicated. Biofeedback therapy is effective in patients with dyssynergic defecation. In patients with other
evacuation disorders, rectally administered laxatives or transanal irrigation should be attempted. Surgery is restricted to the
minority of CC patients with very severe symptoms not responding to conservative treatment.
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Introduction
Chronic constipation (CC) is an extremely common dis-
order with an estimated prevalence ranging between
2% and 24%.1,2 The prevalence of CC increases with
age and may reach 80% in nursing home residents.2
Constipation has severe consequences for the quality
of life of those affected and costs to individual patients
and to society in general are significant.
CC is a symptom-based diagnosis and several
definitions have been proposed. Constipation is either
primary (also termed functional or idiopathic) or
secondary to other conditions. Today, the ROME III
criteria are the most commonly used definition of
chronic idiopathic constipation (Table 1) while second-
ary constipation is less well defined.3 The ROME III
criteria distinguish between CC and constipation pre-
dominant irritable bowel syndrome (IBS-C). The main
difference is that pain is a major component of IBS-C.
In clinical practice the distinction between the two
conditions can be extremely difficult and sometimes
impossible. Several biomarkers have been proposed
for the purpose, but none have been sufficiently vali-
dated or widely used.
Within the last decade our understanding of the
pathophysiology behind CC has improved and several
new drugs or treatment principles have been
introduced. The following is a clinically orientated
review of modern management of CC.
Pathophysiology of constipation
CC is often classified from the objective test used.
From transit studies, CC is commonly classified as
slow transit constipation with abnormally slow transit
throughout the whole colorectum, outlet disorder where
transit is mainly delayed in the distal colorectum, or
normal transit constipation where the subject has symp-
toms of constipation but colorectal transit time is
normal.4
From anorectal physiology tests a subgroup of
patients can be identified as having dyssynergic con-
traction of the pelvic floor during defecation. Others
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have rectal hyposensation determined by rectal balloon
distension,5 while some have structural disorders found
on evacuation proctography or magnetic resonance
imaging. Very often more than one abnormality can
be found in the same patient and abnormal tests are
common among healthy subjects without symptoms of
CC. Thus, no test can stand alone in the evaluation of
individual patients.
Colorectal contractions are generated by the intersti-
tial cells of Cajal. The most important contraction pat-
terns are (a) segmental contractions located to short
segments of the colon with the main function of
mixing colonic contents and (b) high amplitude colonic
contractions that move colonic contents through large
distances and often precede defecation.
The number of interstitial cells of Cajal is reduced in
some patients with CC. Recent studies with fibre optic
high resolution manometry have provided detailed
information about motility in patients with slow transit
constipation. Thus, patients with CC appear to have (a)
significantly reduced amplitude of colonic contractions,
including fewer high amplitude colonic contractions,
(b) reduced gastrocolonic response after meals, and
(c) significantly more retrograde contractions.6
Outlet dysfunction is a common form of constipa-
tion often non-responsive to conservative treatment.
The main symptoms are straining, difficult rectal evacu-
ation or a sense of incomplete evacuation. It may affect
up to 50% CC patients referred to tertiary care.7
Patients with outlet dysfunction can be divided into
those with structural causes (i.e. large rectocele, rectal
prolapse or perineal descensus) and patients with a
functional defecation disorder, mostly dyssynergic defe-
cation.8 Dyssynergic defecation is characterized by
inability to coordinate abdominal muscle pushing
effort and pelvic floor muscle relaxation on straining.
Severe outlet disorder can also be seen with damage to
the reflex arch between the colorectum and the spinal
cord.9
A number of conditions can cause secondary consti-
pation (Table 2). Several drugs have constipation as a
common side effect. Some of the most commonly used
are opioids, NSAIDs, calcium antagonists, beta
blockers, diuretics, anticholinergics, anticonvulsants,
iron, 5-HT antagonists, psychotropic drugs and
anti-rheumatic agents.
Basic clinical evaluation of patients with CC
Most patients with CC should be treated in primary
care. If alarm symptoms indicating colorectal cancer
or other organic disease are present, endoscopy
should be performed according to local guidelines.
The anamnesis should include: duration of symp-
toms, comorbidity, previous gastrointestinal or anorec-
tal surgery, stool frequency, stool consistency, difficult
rectal evacuation, sense of incomplete evacuation,
straining, sense of obstruction during defecation, digital
evacuation of the rectum, vaginal digitation to empty
the rectum, digital support of the perineum, abdominal
massage, unsuccessful attempts at defecation, abdom-
inal pain, bloating, pain during evacuation, signs of
rectal prolapse, enterocele or cystocele, previous treat-
ment, concomitant medication, and impact on social
activities and quality of life. A brief assessment of
diet, fluid intake and physical activity should be
included. Furthermore, symptoms of bladder or
Table 2. Examples of conditions causing secondary constipation
 Congenital malformations
 Structural causes or mechanical obstruction
 Colon cancer
 Benign stricture
 Rectocele, enterocele, rectal prolapse
 Megacolon
 Fissures
 Metabolic
 Hypothyroidism
 Hypercalcaemia
 Hypokalaemia
 Uraemia
 Coeliac disease
 Myopathies
 Scleroderma
 Amyloidosis
 Neuropathies
 Spinal injury
 Myelomeningocele
 Multiple sclerosis
 Diabetic neuropathy
 Cerebrovascular disease
 Parkinson’s disease
 Complications from surgery or irradiation therapy
 Depression
 Cognitive impairment
 Immobility
Table 1. Definition of chronic constipation according to the ROME
III criteria
(1) Including 2 of the following symptoms:
 straining during 25% of toilet visits
 lumpy, hard faeces on 25% of defecations
 feeling of incomplete emptying during 25% of defecations
 feeling of anorectal obstruction/blockage 25% of defecations
 requirement of manual stimulation 25% of defecations
 <3 defecations per week.
(2) Loose stools are not achievable without laxatives.
(3) Symptoms do not fit the criteria for irritable bowel syndrome.
Symptoms must be present for 6 months.
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gynaecological disorders should be noted. A history of
physical abuse or psychiatric disorder may cause special
considerations about therapy.
Abdominal palpation should be performed to
exclude abdominal mass. Digital anorectal examination
should be performed at rest to exclude tumours in the
ampulla or anal canal. Digital anorectal examination is
performed during attempted defecation to identify
pelvic floor contraction. If difficult evacuation is a
main complaint, bimanual vaginal and rectal examin-
ation can be performed to identify rectocele. Patient
reporting symptoms of rectal prolapse should sit on a
commode and be asked to bear down for two minutes
to identify a rectal prolapse.
In most patients treatment can be initiated after the
simple evaluation described above.
Advanced evaluation of patients with CC
Patients not responding to basic treatment with lifestyle
modifications, laxatives or other medical treatment as
described below should be considered for more
advanced evaluation. The same is true for patients
with symptoms of severely obstructed defecation or
underlying structural disorders. Advanced evaluation
of patients with CC usually includes: assessment of
colorectal transit time, anorectal physiology tests, and
imaging of the rectum and the pelvic floor.
The most commonly used method for estimating
colorectal transit time is radio opaque markers.
Several protocols exist but basically three variants are
used: (A) single intake of radiopaque markers followed
by a single abdominal X-ray (usually after four days),
(B) intake of radiopaque markers on successive days
(usually three or six days) followed by a single abdom-
inal X-ray on day four or seven, or (C) single intake of
radiopaque markers followed by successive abdominal
X-rays. Method A is simple and easy to both patients
and staff, but it only provides semi-quantitative esti-
mates of colorectal transit time.10 Method B provides
quantitative information on total and segmental colo-
rectal transit times (in hours or days), but requires that
the patient remembers to take the markers at the cor-
rect time.11 Method C is usually not used because it
requires more than one X-ray and exposes the subjects
to more irradiation than the other methods. Examples
of normal and prolonged colorectal transit times are
shown in Figure 1.
The wireless motility capsule and the novel Motilis
3D-Transit system hold promise for future evaluation
of regional and whole-gut motility and transit times in
CC.12,13
Anorectal physiology tests in patients with CC are
different from those used in patients with faecal incon-
tinence. In CC the following tests are commonly
used: assessment of rectal sensation, rectal capacity
and compliance during balloon distension, anal
manometry during rectal balloon distension and anal
sphincter electromyography during rectal balloon
evacuation.14
Rectal sensitivity and capacity are usually tested by
rectal distension by a balloon or a bag.14 The aim is to
identify subjects with a hyposensate rectum. Usually,
volumes are registered at ‘first sensation’, ‘urge to
defecate’ and ‘maximum tolerable volume’. From
volume–pressure relations, rectal compliance can be
computed. Even though commonly used, rectal disten-
sion with a balloon is hampered by inherent sources of
error.14 Investigation with a barostat is more accurate
but also very time consuming. A new ‘fast barostat’ has
recently been introduced.15
Anal manometry during rectal balloon distension is
mainly performed to identify patients with
Hirschsprung’s disease. Absence of the rectoanal
inhibitory reflex, mediating internal anal sphincter
relaxation during rectal distension, indicates
Hirschsprung’s disease but deep biopsies are necessary
to confirm the diagnosis.
Electromyography of the external anal sphincter
during attempted evacuation of a rectal balloon is per-
formed to identify paradox contraction of the pelvic
floor during defecation.8 The inability to expel the bal-
loon supports the diagnosis.16 Unfortunately, there is
considerable disagreement between various tests of eva-
cuatory function.17
The anatomy of the rectum and surrounding pelvic
organs during defecation are usually evaluated with
evacuation or magnetic resonance proctography.18,19
Either modality is indicated if structural disorders,
e.g. rectocele or rectal intussusception, are suspected
as a cause of difficult evacuation. Regardless of meth-
ods, structural disorders are extremely common in
Figure 1. Examples of normal (a) and prolonged colorectal transit
time in a patient with slow transit constipation (b).
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asymptomatic subjects and their presence does not
necessarily explain the symptoms or indicate surgical
treatment.
The main limitations with all anorectal physiology
tests are the extreme variability between subjects and
substantial overlap between asymptomatic healthy sub-
jects and patients. However, the identification of
patients with Hirschsprung’s disease and the much
more common patients with pelvic floor dyssynergia
is important because the conditions should be treated
with surgery and biofeedback, respectively.
Lifestyle modifications for CC
CC is associated with low intake of fibre and fluid.20
Dietary fibres are resistant to hydrolysis by enzymes in
the small intestine and pass unabsorbed to the colon,
where they retain water and add bulk to the stools.
Increased intake of fibre can reduce colonic transit
time and alleviate symptoms.21,22 Side effects mainly
include the production of gas causing abdominal dis-
comfort and flatulence.21,22 This is mainly observed
with short water-soluble fibres. Unless the subject is
dehydrated, moderate increase of water intake does
not affect colorectal function or reduce symptoms of
constipation. An intake of two litres of water daily
will, however, enhance the positive effects of dietary
fibre.23
Constipation is strongly associated with immobility.
In healthy subjects physical activity stimulates colorec-
tal motility thereby reducing colonic transit time.24 In
patients with chronic idiopathic constipation, moderate
physical activity 30–60min per day improves stool con-
sistency.25 In patients with drug-induced constipation,
it should be considered if the drug can be substituted
with another less likely to cause constipation.
Basic treatment with laxatives
Laxatives are grouped according to their mechanism of
action (Table 3). Osmotic laxatives contain non-
absorbable ions and molecules that retain water
within the colon thereby increasing stool volume and
decreasing consistency. Commonly used osmotic laxa-
tives are lactulose, magnesium oxide and polyethylene
glycol (PEG). Peristalsis inducing laxatives stimulate
the secretion of fluids and electrolytes that enhance
peristalsis. These include bisacodyl and sodium picosul-
fate. Rectally administered laxatives induce rectal con-
tractions through chemical stimulation of the mucosa.
Commonly used rectal administered laxatives are phos-
phate enema, Microlax and bisacodyl, or glycerol
suppositories.
Most commonly used laxatives have been used for
several decades and only few publications have
documented their effect. Thus, no placebo controlled
study exists on the efficacy of magnesium.
Randomised trials have shown that lactulose in super-
ior to placebo.26 Also, placebo controlled trials have
found that PEG reduces symptoms of CC.27,28
Unfortunately, no study has been performed to com-
pare the most commonly used laxatives to each other or
to investigate whether there is an additional effect from
combining laxatives. Therefore, choice of laxative will
be determined by local preferences and cost.
In patients with difficult rectal evacuation and in
patients with the combination of constipation and
faecal incontinence, suppositories or mini enema
should be attempted.
Prokinetics and secretagogues
Prucalopride is a 5HT-4 agonist with enterokinetic
properties. In randomized placebo-controlled, clinical
trials, prucalopride reduced colorectal transit times
and alleviated symptoms in patients with idiopathic
CC.29
Linaclotide and lubiprostone enhance secretion from
the gut wall and thereby reduce colorectal transit time
and symptoms. Both linaclotide and lubiprostone have
proven superior to placebo in double-blind placebo-
controlled trials among patients with CC.30–32 Even
though the effects of prucalopride, linaclotide and lubi-
prostone against CC are well-documented, the number
needed to treat in order to reach a meaningful clinical
response is approximately 3–5. In Europe, linaclotide
Table 3. Basic and advanced treatment of chronic constipation
Lifestyle modifications Increased intake of fibre
Sufficient intake of fluid
Increased physical activity
First line treatment Oral laxatives (osmotic, lubricating or
stimulant)a
Rectal laxatives (suppositories or
mini enema)b
Second line treatment Prokinetics (prucalopride)
Secretory agents (linaclotide,
lubiprostone)
Biofeedbackc
Transanal irrigationd
Advanced/experimental
treatment
Sacral nerve stimulation
The Malone antegrade colonic
enemad
Colostomy
Procedures for correcting rectocele
aNo data exist to recommend one oral laxative against others.
bFor patients with symptoms of evacuatory dysfunction.
cFor patients with dyssynergic defecation.
dMainly for patients with constipation secondary to neurological disorders.
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has so far only been approved for IBS-C, but in several
other countries including the US it has been approved
on wider indication also including CC.
Biofeedback
Biofeedback (BFB) therapy is an instrument-based
conditioning treatment which aims to restore a
normal pattern of defecation by training the patient
on adequate use and coordination of abdominal and
pelvic floor muscles. In addition, some centres focus
on enhancing rectal sensory perception, but this is with-
out clear evidence of incremental benefit.
It has been debated whether BFB has a positive
effect on constipation in general or only in those with
functional defecation disorder.8 However, recent data
show that BFB has long-term effect against constipa-
tion due to functional defecation disorder only.33
Recently, randomized controlled clinical trials have
provided unequivocal evidence that biofeedback ther-
apy is effective both short and long-term for severe
constipation due to dyssynergic defecation.34–36 Thus,
instrument-based biofeedback is more effective than
pelvic floor exercises (Kegel’s training), sham biofeed-
back, conservative treatment and laxatives
(Macrogol). Potential limitations are the access to
high level of therapist expertise and patient
motivation.
Transanal irrigation
Transanal irrigation (TAI) with a water enema installed
through the rectum was introduced against severe con-
stipation and faecal incontinence in children with spina
bifida or anorectal malformations.37 In adult patients
the primary indication is neurogenic bowel dysfunction.
When performed correctly, TAI will empty the color-
ectum distal to the splenic flexure.38 In a randomized
trial among patients with severe constipation and faecal
incontinence after spinal cord injury, TAI was superior
to ‘best standard care’.39 The procedure is, however,
time consuming as most patients need to perform it
every second day and the time spent at each procedure
is 30–45min. Thus, the proportion of patients continu-
ing treatment after three years is approximately 50%.40
Furthermore, TAI may be useful in patients with
evacuation disorders after anorectal surgery or con-
genital malformations.41
Surgical treatment of CC
Sacral nerve stimulation (SNS) is a minimally invasive
procedure whereby an electrode is placed in a posterior
foramen of the sacral bone. SNS may alleviate CC in
approximately 50% of highly selected patients.42 The
mechanism of action for SNS in CC remains obscure
and further studies are need to confirm the clinical
effects.
By the Malone operation, also termed the antegrade
colonic enema (ACE), a small stoma is constructed
from the appendix.43 Through the appendicostomy a
catheter can be inserted to administer the enema in
the caecum. Usually 1.000ml are given every second
day to empty the whole colorectum.44 If the patient
no longer has the appendix, a ‘neoappendix’ can be
created from ileum or part of the caecum. The ACE
is mainly used in patients with severe constipation or
faecal incontinence secondary to neurological dis-
orders. The procedure is safe but minor complications
are extremely common, i.e. experienced by up to 80%,
especially because of stenosis of the appendicostomy.
The ACE is only used at few institutions and high
reversal rates have been reported. However, with thor-
ough selection and instructions of patients long-term
results may be good.45
Colectomy with ileorectal anastomosis is reserved
for a very small group of patients with severe symptoms
not responding to other kinds of treatment. In most
cases, colectomy will increase the frequency of defeca-
tion and reduce the use of laxatives.46 However, the
quality of studies on the subject is very variable and
guidelines for selection of patients with CC for colec-
tomy do not exist.46 The pathophysiology of CC is
complex, including some with pan-enteric dysfunction,
and often colectomy does not solve the clinical prob-
lem. Furthermore, the rate of perioperative complica-
tions has been reported as high as 43% with a
readmission rate after 30 days of 29%.47
Special considerations in patients with
secondary constipation
Constipation is very common in patients with neuro-
logical disorders. Thus, up to 95% of patients with
spinal cord injury suffer from constipation,48,49 includ-
ing 65% who have to perform digital stimulation or
evacuation of the anorectum.49 Constipation is also
reported by approximately 40% of patients with mul-
tiple sclerosis,50 and by 79% of patients with spina
bifida.51 The patients very often suffer from a combin-
ation of faecal incontinence and constipation.48–51
Therefore, treatment will aim at emptying the rectosig-
moid either through digital anorectal stimulation or
with mini enema (Clysma). If this fails TAI is an
option.39 A pilot trial has indicated that prucalopride
has an effect against constipation secondary to spinal
cord injury.52 Patients not responding to conservative
treatment or patients with very poor mobility and hand
function can be offered ACE,45 or a colostomy/
ileostomy.
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Patients with Parkinson’s disease have constipation
partly because of reduced number dopaminergic
neurons in the colon and autonomic neuropathy and
partly because of dystonia of the striated external anal
sphincter muscle.53,54 The main symptom is difficult
evacuation.55 The severity of constipation is associated
with the severity of Parkinson’s disease.55 Treatment
will usually include dietary fibre in combination with
laxatives or prokinetics.56
Some patients with myopathy of the gut, especially
patients with systemic scleroderma, may have constipa-
tion while others have diarrhoea or faecal incontin-
ence.57 Diabetic autonomic neuropathy may affect
transit through all regions of the gastrointestinal
tract. Some patients have severe constipation while
others have intractable diarrhoea.58 As with patients
with myopathy, objective information about regional
transit times is important in order to target treatment
which usually includes laxatives or prokinetics.
Treatment with opioids will usually cause constipa-
tion. Standard treatment with laxatives should be
attempted. If this fails, prucalopride or the mu opioid
receptor antagonist naloxegol should be attempted.59,60
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